全文获取类型
收费全文 | 8880篇 |
免费 | 744篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 186篇 |
儿科学 | 397篇 |
妇产科学 | 247篇 |
基础医学 | 986篇 |
口腔科学 | 243篇 |
临床医学 | 691篇 |
内科学 | 2334篇 |
皮肤病学 | 262篇 |
神经病学 | 647篇 |
特种医学 | 263篇 |
外科学 | 1516篇 |
综合类 | 27篇 |
一般理论 | 3篇 |
预防医学 | 759篇 |
眼科学 | 201篇 |
药学 | 417篇 |
中国医学 | 34篇 |
肿瘤学 | 424篇 |
出版年
2023年 | 39篇 |
2022年 | 79篇 |
2021年 | 247篇 |
2020年 | 137篇 |
2019年 | 300篇 |
2018年 | 292篇 |
2017年 | 208篇 |
2016年 | 221篇 |
2015年 | 231篇 |
2014年 | 317篇 |
2013年 | 409篇 |
2012年 | 468篇 |
2011年 | 555篇 |
2010年 | 370篇 |
2009年 | 290篇 |
2008年 | 447篇 |
2007年 | 488篇 |
2006年 | 504篇 |
2005年 | 475篇 |
2004年 | 440篇 |
2003年 | 414篇 |
2002年 | 395篇 |
2001年 | 315篇 |
2000年 | 366篇 |
1999年 | 257篇 |
1998年 | 67篇 |
1997年 | 58篇 |
1996年 | 59篇 |
1995年 | 50篇 |
1994年 | 39篇 |
1993年 | 39篇 |
1992年 | 135篇 |
1991年 | 117篇 |
1990年 | 105篇 |
1989年 | 100篇 |
1988年 | 55篇 |
1987年 | 54篇 |
1986年 | 47篇 |
1985年 | 50篇 |
1984年 | 35篇 |
1983年 | 29篇 |
1979年 | 28篇 |
1975年 | 20篇 |
1974年 | 18篇 |
1973年 | 24篇 |
1972年 | 22篇 |
1971年 | 21篇 |
1970年 | 19篇 |
1969年 | 22篇 |
1968年 | 19篇 |
排序方式: 共有9637条查询结果,搜索用时 15 毫秒
101.
Gonzálvez Piñera J Ruiz Cano R García Rodríguez MR Fernández Córdoba MS Crusat Braña S Sango Lamban M 《Cirugía pediátrica : organo oficial de la Sociedad Espa?ola de Cirugía Pediátrica》2000,13(3):126-128
Kikuchi-Fujimoto's disease is a rare self-limited condition of young adults that usually involves the cervical lymph nodes and is associated with fever, rash and some haematological alterations. Diagnosis is based on characteristic pathologic findings that permit differentiation of this disease from lymphoma, systemic lupus erythematous and infectious lymphadenopathies. We describe a case of 7 year-old female presenting with cervical localization of Kikuchi-Fujimoto's disease. To our knowledge, this case results the earliest affection of this disease. Our proposal with this article is to remind the pediatricians and pediatric surgeons of this poorly recognized entity when children ask for cervical masses and fever. 相似文献
102.
Paredes Esteban RM Velasco Sánchez B Martínez-Victoria Muñoz JM Cuevas C García Ruiz M 《Cirugía pediátrica : organo oficial de la Sociedad Espa?ola de Cirugía Pediátrica》2000,13(4):170-171
We present 2-year-old patient with a allopecia lesions in scalp, and clinique diagnostic of Cutis Aplasia. The anatomopathologic study have diagnosed the lesions as Acquired Progressive Lymphangioma (APL). Is a rare vascular tumour that has a tendency to appear in childhood an to progress slowly over the years. It could present as a solitary erythematous macule or plaque and a simple excision is usually curative. Our patient is the youngest reported in the literature. 相似文献
103.
Marta Ruiz Hiroya Kobayashi Juan José Lasarte Jesús Prieto Francisco Borrás-Cuesta Esteban Celis Pablo Sarobe 《Clinical cancer research》2004,10(8):2860-2867
PURPOSE: The purpose of this research was to identify promiscuous T-helper cell determinants (THd) from carcinoembryonic antigen (CEA) to be used to prime T-cell help for cancer therapy. CEA was selected because this antigen is expressed in an important variety of carcinomas. EXPERIMENTAL DESIGN: Potential promiscuous THd from CEA were predicted using available computer algorithms. Predicted peptides were synthesized and tested in binding experiments to different HLA-DR molecules. Binder peptides were then used to prime T-cell responses both in vitro and in vivo. RESULTS: Twenty 15-mer peptides from CEA were predicted to bind to different HLA-DR molecules. The promiscuous character of these peptides was demonstrated in binding experiments. Fifteen of 20 peptides tested were able to bind to HLA-DR4, but only CEA (625-639) was shown to be presented after processing of recombinant CEA. CEA (625-639) was also found to be presented by HLA-DR53. Moreover, immunization of HLA-DR4 transgenic mice with CEA (625-639) in conjunction with class I epitope OVA (257-264), induced a CTL response specific of OVA (257-264). CONCLUSIONS: CEA (625-639) might be a relevant promiscuous THd peptide for cancer therapy. 相似文献
104.
Dina Chelouche Lev Amir Onn Vladislava O Melinkova Claudia Miller Valerie Stone Maribelis Ruiz Eric C McGary Honnavara N Ananthaswamy Janet E Price Menashe Bar-Eli 《Journal of clinical oncology》2004,22(11):2092-2100
PURPOSE: In recent years, the incidence of cutaneous melanoma has increased more than that of any other cancer. Dacarbazine is considered the gold standard for treatment, having a response rate of 15% to 20%, but most responses are not sustained. Previously, we have shown that short exposure of primary cutaneous melanoma cells to dacarbazine resulted in the upregulation of interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF). The purpose of the present study was to determine how long-term exposure of melanoma cells to dacarbazine would affect their tumorigenic and metastatic potential in vivo. MATERIALS AND METHODS: The primary cutaneous melanoma cell lines SB2 and MeWo were repeatedly exposed in vitro to increasing concentrations of dacarbazine, and dacarbazine-resistant cell lines SB2-D and MeWo-D were selected and examined for their ability to grow and metastasize in nude mice. RESULTS: The dacarbazine-resistant cell lines SB2-D and MeWo-D exhibited increased tumor growth and metastatic behavior in vivo. This increase could be explained by the activation of RAF, MEK, and ERK, which led to the upregulation of IL-8 and VEGF. More IL-8, VEGF, matrix metalloproteinase-2 (MMP-2), and microvessel density (CD-31) were found in tumors produced by SB2-D and MeWo-D in vivo than in those produced by their parental counterparts. No mutations were observed in BRAF. CONCLUSION: Our results have significant clinical implications. Treatment of melanoma patients with dacarbazine could select for a more aggressive melanoma phenotype. We propose that combination treatment with anti-VEGF/IL-8 or MEK inhibitors may potentiate the therapeutic effects of dacarbazine. 相似文献
105.
Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. 总被引:1,自引:0,他引:1
Beatriz Martinez-Delgado Barbara Meléndez Marta Cuadros Javier Alvarez Jose Maria Castrillo Ana Ruiz De La Parte Manuela Mollejo Carmen Bellas Ramon Diaz Luis Lombardía Fatima Al-Shahrour Orlando Domínguez Alberto Cascon Mercedes Robledo Carmen Rivas Javier Benitez 《Clinical cancer research》2004,10(15):4971-4982
PURPOSE: T-Cell lymphomas constitute heterogeneous and aggressive tumors in which pathogenic alterations remain largely unknown. Expression profiling has demonstrated to be a useful tool for molecular classification of tumors. EXPERIMENTAL DESIGN: Using DNA microarrays (CNIO-OncoChip) containing 6386 cancer-related genes, we established the expression profiling of T-cell lymphomas and compared them to normal lymphocytes and lymph nodes. RESULTS: We found significant differences between the peripheral and lymphoblastic T-cell lymphomas, which include a deregulation of nuclear factor-kappaB signaling pathway. We also identify differentially expressed genes between peripheral T-cell lymphoma tumors and normal T lymphocytes or reactive lymph nodes, which could represent candidate tumor markers of these lymphomas. Additionally, a close relationship between genes associated to survival and those that differentiate among the stages of disease and responses to therapy was found. CONCLUSIONS: Our results reflect the value of gene expression profiling to gain insight about the molecular alterations involved in the pathogenesis of T-cell lymphomas. 相似文献
106.
107.
Neurotrophic factors are compounds that enhance neuronal survival and differentiation. Most of these compounds exert their pharmacological actions on selective types of neurons, and therefore, are considered promising new therapeutic agents for the treatment of different neurodegenerative disorders characterized by selective degeneration of certain neuronal groups. Those compounds have been used in humans for several neurological disorders including amyotrophic lateral sclerosis--ciliary derived neurotrophic factor (CNTF) and brain derived neurotrophic factor (BDNF), Alzheimer's disease and peripheral neuropathy--nerve growth factor (NGF) and Parkinson's disease (PD)--glial derived neurotrophic factor (GDNF). In spite of well founded clinical experiments by previous experimental work in animal models some of these trials have been negative. For instance, animal models of PD have shown that several neurotrophic factors, including GDNF and other compounds, reduce apoptosis and increase resistance of dopamine neurons to neurotoxins in vitro. These compounds prevent or recover the damage to dopamine neurons of rodents and primates produced by chemical or mechanical acute lesions including 6-OH-DA, MPTP, methamphetamine and axotomy. The differences between the promising results obtained in experimental models and the lack of clinical results or excessive toxicity found in humans could be attributed to the following reasons: (a) Lack of relevance between the pathogenesis of the experimental lesion and the corresponding neurodegenerative disorder. (b) Poor correlation between results obtained in acute, self-limited, selective deficit produced to experimental animals and those available in more complex, chronic and progressive disorders involving patients. (c) Inadequate delivery of the active product to the target area in the human brain. (d) Poor information from acute experiments in animals which does not predict long-term effects of chronic infusion in humans. Further experimental work, therefore, is needed to transfer these neurotrophic factors to the clinic. 相似文献
108.
109.
110.